GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XBUL:EVT) » Definitions » Effective Interest Rate on Debt %

Evotec SE (XBUL:EVT) Effective Interest Rate on Debt % : 3.93% (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Evotec SE Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Evotec SE's annualized positive value of Interest Expense for the quarter that ended in Mar. 2025 was лв18 Mil. Evotec SE's average total debt for the quarter that ended in Mar. 2025 was лв457 Mil. Therefore, Evotec SE's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 was 3.93%.


Evotec SE Effective Interest Rate on Debt % Historical Data

The historical data trend for Evotec SE's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Effective Interest Rate on Debt % Chart

Evotec SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.85 1.78 2.50 2.10 2.14

Evotec SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 1.98 1.61 3.75 3.93

Competitive Comparison of Evotec SE's Effective Interest Rate on Debt %

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's Effective Interest Rate on Debt % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Evotec SE's Effective Interest Rate on Debt % falls into.


;
;

Evotec SE Effective Interest Rate on Debt % Calculation

Evotec SE's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2023 )+Total Debt  (A: Dec. 2024 ))/ count )
=-1  *  -21.117/( (1177.173+800.605)/ 2 )
=-1  *  -21.117/988.889
=2.14 %

where

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=896.896 + 280.277
=1177.173

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=708.918 + 91.687
=800.605

Evotec SE's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2024 )+Total Debt  (Q: Mar. 2025 ))/ count )
=-1  *  -17.944/( (800.605+113.533)/ 2 )
=-1  *  -17.944/457.069
=3.93 %

where

Total Debt  (Q: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=708.918 + 91.687
=800.605

Total Debt  (Q: Mar. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 113.533
=113.533

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Evotec SE  (XBUL:EVT) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Evotec SE Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Evotec SE's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE Business Description

Industry
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.